Epoqe Pharma ApS: Financial statements 2022
CVR: 42443670
Source: annual report 2022, Danish Business Authority
04/06/2021 – 30/06/2022
Epoqe Pharma ApS (CVR 42443670) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -17,070 and a net result of DKK -18,026. Equity in the 2022 report amounted to DKK 133,079. The solvency ratio was 91.7%.
- Gross Profit
- DKK -17,070
- Profit/Loss
- DKK -18,026
- Equity
- DKK 133,079
- Total Assets
- DKK 145,079
Official annual report
Keep an eye on Epoqe Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout Epoqe Pharma ApS
Epoqe Pharma ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Patentselskabet af 31. maj 2021 ApS.. The management consists of Mark Stephen Sumeray. The board consists of Anders Gaarsdal Holst (chair), Henrijette Elsebeth Richter, Lars Gredsted and Mark Stephen Sumeray. The company's owners include LUNDBECKFOND INVEST A/S, Helms & Sams ApS and CMCGreenhouse ApS. According to the 2025 annual report, the company had an average of 3 employees. In 2025, the company reported a gross profit of DKK -13,719,778 and a net result of DKK -13,943,884 compared with DKK -135,919 the year before. Equity in the 2025 report amounted to DKK 30,042,156.